Biolinerx.

BioLineRx does not assume any obligation to update any forward-looking statements unless required by law. Contacts: United States John Lacey BioLineRx +1-781-392-5514 [email protected]

Biolinerx. Things To Know About Biolinerx.

About BioLineRx BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company's first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel. For a complete picture of AGI-134’s drug-specific PTSR and LoA scores, buy the report here.BioLineRx exits 2023 in a very strong position with several advantages. A successful start to the Aphexda launch in the United States, formalization of an agreement with a dominant partner in Asia driving development of motixafor-tide in multiple indications, internal development of a portfolio offering multiple programs and two candidates sup-ported by a …BioLineRx does not assume any obligation to update any forward-looking statements unless required by law. [i] ASCO Cancer.Net. Cancer.Net Editorial Board Approval March 2023.

Jul 17, 2023 · About BioLineRx BioLineRx Ltd. is a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company is advancing a pipeline of investigational medicines for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide ...BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide. PDF Version. 24 May 2023.

Oct 12, 2023 · BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investigational Candidate Motixafortide. PDF Version. 24 May 2023. TEL AVIV, Israel, Aug. 30, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life …

On August 27, 2023, BioLineRx Ltd. entered into a license agreement with Hong Seng Technology Limited and Guangzhou Gloria Biosciences Co., Ltd. pursuant to which the Company granted HST an exclusive, royalty-bearing, proprietary license with respect to the intellectual property rights and know-how associated with motixafortide (BL …BioLineRx. Chief Executive Officer - Phil Serlin. Located in Modi’in, Israel, BioLineRx creates therapeutics with a focus on oncology. Currently, its pipeline consists of two candidates in the ...Powered by our full spectrum of drug development capabilities, BioLineRx is pursuing life-changing therapies designed to deliver meaningful therapeutic benefits to patients with certain cancers and rare diseases. Discover our pipeline. Now Approved in the U.S. The FDA has approved APHEXDA™.Powered by our full spectrum of drug development capabilities, BioLineRx is pursuing life-changing therapies designed to deliver meaningful therapeutic benefits to patients with certain cancers and rare diseases. Discover our pipeline. Now Approved in the U.S. The FDA has approved APHEXDA™. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that pilot phase data from ...

BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business, approved products and therapeutic candidates; the scope of protection BioLineRx is able

Driving innovative therapeutics across the finish line. Powered by our full spectrum of drug development capabilities, BioLineRx is pursuing life-changing ...

28 thg 9, 2023 ... TEL AVIV, Israel, September 28, 2023 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing ...Yet, BLRX has fallen. Down 33% during that time period. I can see it returning below the $1 price range and a buyout (if it happens) at below $2.00 a share. It's too bad. I was a big believer in BLRX. But, it's way past time to sell. 5 comments. 1. Posted by 2 months ago.BioLineRx Ltd. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) December 31, September 30, 2022. 2023. in USD thousands. AssetsBioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.:םיפסונ םיטרפל ²£ ¨ ©² ¨ LifeSci Advisors, LLC +972-54-476-4945 [email protected], Valuation & Revenue. 2 Fundings. BioLineRx has raised $9M over 2 rounds. BioLineRx's latest funding round was a IPO for $50M on February 7, 2007.Mar 15, 2023 · BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023 ...Jan 18, 2022 · TEL AVIV, Israel, Jan. 18, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ-CM: BLRX) (TASE: BLRX) a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has completed a successful pre-New Drug Application (NDA) meeting with the US Food and Drug Administration (FDA) regarding Motixafortide as a novel stem-cell mobilization agent for autologous bone ... Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API. C4 Therapeutics's main competitors include Acrotech Biopharma, TrueBinding, Achilles Therapeutics and BioLineRx. Compare C4 Therapeutics to its competitors by revenue, employee growth and other metrics at Craft.BioLineRx is a biopharmaceutical company focused on oncology. It in-licenses compounds, develops them through pre-clinical and/or clinical stages, and then …TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company's COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with KEYTRUDA ® (pembrolizumab) and chemotherapy in patients with second-line ...Gulam A. Manji reported clinical trials funding from Genentech Roche, Merck, Plexxikon, Regeneron, and BioLineRx, research funding from Genentech Roche, consultanting for Arcus Biosciences, BioLineRx, and Ipsen, and advisory board member for Pfizer and CEND Pharm, all unrelated to the work in this manuscript. ReferencesTEL AVIV, Israel, January 25, 2016 /PRNewswire/ -- BioLineRx Ltd. , a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising... -January 25, 2016 at 07:01 am EST - MarketScreener

About BioLineRx. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in …

About BioLineRx. BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.Background: Elderly patients (pt) with acute myeloid leukemia (AML) or pts with relapsed/refractory (R/R) AML have dismal outcomes.Venetoclax (VEN) synergizes with hypomethylating agents (HMA) and is now an approved combination for newly diagnosed (ND) AML in older/intensive chemotherapy (IC)-ineligible patients.BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase. Jul. 17. CI. BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023. May. 24. CI. BioLineRx Ltd. Reports Earnings Results for the Full Year Ended ...31 thg 10, 2023 ... BioLineRx Ltd. has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. for the development of ...Jun 30, 2023 · BioLineRx Ltd. is a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases. The company is advancing a pipeline of investigational medicines for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported its unaudited financial results for the first quarter ended March 31, 2023 ...BioLineRx overview. BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML.

The sponsor BioLineRx participated in the conception of this study. Data were analyzed and interpreted by BioLineRx in collaboration with the academic authors. The sponsor staff, M.H. and B.B ...

BioLineRx is also eligible to receive tiered double-digit royalties on net sales. In addition, the transaction included an equity investment of $14.6 million in BioLineRx through the purchase of newly issued American Depositary Shares (ADSs) at a price of $2.136 per ADS in a private placement. No warrants were issued in the transaction.

Get the latest BioLineRx Ltd. (BLRX) stock news and headlines to help you in your trading and investing decisions.First Quarter 2023 Financial Results. Research and development expenses for the three months ended March 31, 2023 were $3.7 million, a decrease of $0.7 million, …BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 12, 2020. In addition, any forward-looking statements represent BioLineRx's views only as of the date ofAbout BioLineRx. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow …15 thg 1, 2020 ... BioLineRx is currently in the midst of a Phase I/IIa clinical study testing intratumoral injections of AGI-134 in patients. What was the most ...BioLineRx Connect is here for you . BioLineRx is committed to helping you receive access and appropriate financial support once APHEXDA has been prescribed by your doctor. BioLineRx Connect is here to support you by offering the following services: Getting your APHEXDA This includes talking to your insurance company, if necessary, to find out if …Sep 15, 2022 · Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved. TEL AVIV, Israel, Sept. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the Company has entered into a $40 million non-dilutive secured debt financing ... BioLineRx, a 20-year-old company that initially worked on treatments for skin lesions, pivoted in recent years to developing drugs that aid in harvesting of stem cells. Last year, it opened its US ...

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study. For additional information on BioLineRx , please visit the Company's website at www.biolinerx.com , where you can review the Company's SEC filings, press releases ...7 thg 11, 2023 ... Israeli biotech Biolinerx Ltd. will hand off the rights to its stem cell mobilizer, motixafortide, in Asia to China's Gloria Biosciences Co.BioLineRx is a drug development company based in Israel, with a focus on neurological and psychiatric disorders. It was founded in 2003 as a joint venture of Teva, Hadasit Bio …Instagram:https://instagram. ansheiser busch stockvwenx dividendmaa dividendno commission day trading Sep 19, 2022 · About BioLineRx. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company's lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation, has ... best vodka for martinicignaplus dental plan 6 hours ago · Financial Overview. At the end of Q3 2023, BLRX held $28.8 million in total current assets, of which $7.7 million was cash and equivalents, and $18.2 million was short-term bank deposits. Their ... doordash weed TEL AVIV, Israel, Sept. 11, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Aphexda™ (motixafortide) in combination with …BioLineRx's business model and strategic plans for its business, approved products and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its approved products and therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of …